Skip to main content
Premium Trial:

Request an Annual Quote

Daniel O’Day, Michael Onuscheck, Jon Snyder

Premium
The California Healthcare Institute said this week that it has elected Daniel O’Day and Michael Onuscheck to its board of directors.
 
O’Day is currently president and CEO at Roche Molecular Diagnostics in Pleasanton, Calif. Onuscheck is president of the neuromodulation division at Boston Scientific.
 
CHI is a non-profit public-policy research organization representing California’s academic institutions, and biotechnology, medical device, diagnostics, and pharmaceutical firms.
 

 
Arboretum Ventures, headquartered in Ann Arbor, Mich., said this week that it has opened an office at the BioEnterprise facility in Cleveland, and named Jon Snyder manager.
 
Snyder is joining Arboretum as a venture partner from BioEnterprise, where he was worked since January as CEO in residence.
 
Arboretum Ventures is an early-stage venture capital firm focusing on investments in medical technology and healthcare services.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.